OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
• Abstract Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and
Or7A10